Yi Bo Cao

Insight Lifetech Co., Ltd. engages in the manufacture and sale of interventional cardiovascular diagnostic and therapy products. It offers exchange fractional flow reserve (FFR) microcatheters, cardiovascular pressure measurement (CPM) systems, intravascular ultrasound systems, and microcatheters for complex percutaneous coronary intervention (PCI). The company was founded by Xiao Yang Fu and Li Li Chen on December 11, 2015 and is headquartered in Shenzhen, China.

VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.

VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction.

Beijing Microread Genetics Co., Ltd. was founded in 2009 and develops test reagents for clinical, forensic, agricultural, animal husbandry, and research fields. The company is based in Beijing, China.

Hangzhou New Trials Medical Technology Co., Ltd. provides medical technology services. The company is based in Hangzhou, China.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.